Junshi Biotech released its 2026 semi-annual report, achieving operating income of 1,696 billion yuan, an increase of 45.18% over the previous year; net profit attributable to shareholders of listed companies was 21.663 million yuan, turning a year-on-year loss into a profit. The company's Q2 net profit was 42 million, and Q1 net profit was -121 million. Based on this calculation, Q2 net profit turned a month-on-month loss into a profit.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.